Soluble syndecan-3 binds chemokines, reduces leukocyte migration in vitro and ameliorates disease severity in models of rheumatoid arthritis
- Submitting institution
-
University of Keele
- Unit of assessment
- 12 - Engineering
- Output identifier
- 436
- Type
- D - Journal article
- DOI
-
10.1186/s13075-019-1939-2
- Title of journal
- Arthritis Research & Therapy
- Article number
- 172
- First page
- -
- Volume
- 21
- Issue
- 1
- ISSN
- 1478-6354
- Open access status
- Compliant
- Month of publication
- July
- Year of publication
- 2019
- URL
-
https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-019-1939-2
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
8
- Research group(s)
-
-
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- A study that demonstrated that soluble syndecan-3 may have potential therapeutic effects in inflammatory diseases like rheumatoid arthritis. A collaborative project between the Universities of Keele, Bristol and Karl-Franzens, Graz, Austria with support from MRC (DTG K500860/1) and the Oswestry Rheumatology Association (RPG 151). Key findings underpinned follow-on research in collaboration with Stony Brook University, NY, USA with commitment from Keele through an associated PhD studentship for Mairad Jones. Element of this follow-on work drew invited international conference invitation (Matrix Biology Europe 2018) and subsequent publication (Jones et al, 2020).
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -
